Estimating the OncotypeDX score: validation of an inexpensive estimation tool
作者： Anne A. Eaton , Catherine E. Pesce , James O. Murphy , Michelle M. Stempel , Sujata M. Patil
DOI: 10.1007/S10549-016-4069-4
关键词:
摘要: Background OncotypeDX, a multi-gene expression assay, has been incorporated into clinical practice as prognostic and predictive tool. However, its use in resource-constrained international healthcare systems is limited. Here we develop validate simplified model using clinicopathologic criteria to predict OncotypeDX score.
springer.com
sci-hub.se 参考文章(22)
Robert W Carlson, NCCN breast cancer clinical practice guidelines in oncology: an update. Journal of The National Comprehensive Cancer Network. ,(2003)
Laurel A Habel, Steven Shak, Marlena K Jacobs, Angela Capra, Claire Alexander, Mylan Pho, Joffre Baker, Michael Walker, Drew Watson, James Hackett, Noelle T Blick, Deborah Greenberg, Louis Fehrenbacher, Bryan Langholz, Charles P Quesenberry, A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Research. ,vol. 8, pp. 1- 15 ,(2006) , 10.1186/BCR1412
McCarty Ks, Cox Eb, Miller Ls, Konrath J, Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology & Laboratory Medicine. ,vol. 109, pp. 716- 721 ,(1985)
Molly E Klein, David J Dabbs, Yongli Shuai, Adam M Brufsky, Rachel Jankowitz, Shannon L Puhalla, Rohit Bhargava, Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis Modern Pathology. ,vol. 26, pp. 658- 664 ,(2013) , 10.1038/MODPATHOL.2013.36
Bradley M Turner, Kristin A Skinner, Ping Tang, Mary C Jackson, Nyrie Soukiazian, Michelle Shayne, Alissa Huston, Marilyn Ling, David G Hicks, Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Modern Pathology. ,vol. 28, pp. 921- 931 ,(2015) , 10.1038/MODPATHOL.2015.50
Jeffrey S. Ross, Christos Hatzis, W. Fraser Symmans, Lajos Pusztai, Gabriel N. Hortobágyi, Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist. ,vol. 13, pp. 477- 493 ,(2008) , 10.1634/THEONCOLOGIST.2007-0248
Ting Bao, Nancy E. Davidson, Gene expression profiling of breast cancer. Advances in Surgery. ,vol. 42, pp. 249- 260 ,(2008) , 10.1016/J.YASU.2008.03.002
Masahide Kondo, Shu-Ling Hoshi, Takeharu Yamanaka, Hiroshi Ishiguro, Masakazu Toi, Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Research and Treatment. ,vol. 127, pp. 739- 749 ,(2011) , 10.1007/S10549-010-1243-Y
Masakazu Toi, Hiroji Iwata, Takeharu Yamanaka, Norikazu Masuda, Shinji Ohno, Seigo Nakamura, Takahiro Nakayama, Masahiro Kashiwaba, Shunji Kamigaki, Katsumasa Kuroi, Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population Cancer. ,vol. 116, pp. 3112- 3118 ,(2010) , 10.1002/CNCR.25206
Amber A. Guth, Susan Fineberg, Kezhen Fei, Rebeca Franco, Nina A. Bickell, Utilization of Oncotype DX in an Inner City Population: Race or Place? International journal of breast cancer. ,vol. 2013, pp. 653805- 653805 ,(2013) , 10.1155/2013/653805